Brainomix, a U.K.-based medical imaging company focused on artificial intelligence (AI), announced Tuesday, April 3, that it has secured $9.8 million (£7 million) to help market its software for treating stroke victims throughout the world. e-ASPECTS, which Brainomix markets as its flagship software solution, uses AI to provide “fast and standardized assessment of stroke patient CT scans.” It was developed to improve stroke treatment at a lower cost. “Since we started as a spin-out of the University of Oxford we have become a global market leader, with our stroke decision support and workflow tools installed in many leading stroke centres in more than 16 countries,” Michalis Papadakis, Brainomix CEO, said in a prepared statement. “With this investment we will grow around the world and continuously expand Brainomix’s intelligent imaging software for acute stroke care and clinical trials.” FDA approval for e-ASPECTS is pending.
University of Oxford spin-out Brainomix has secured £7m ($9.8m) to market its artificial intelligence (AI) e-Aspects software. The company said the system offers a "fast and standardised assessment of stroke patient CT scans", and helps reduce the cost of treatment. Brainomix's CEO, Michalis Papadakis, said the firm would focus on expanding both its software and global footprint. The company is awaiting approval for the software from the US's Food and Drug Administration.